FTSVEUR

Forty Seven, Inc.

A maker of cancer therapies built on Stanford research, this biotech company developed drugs aimed at the CD47 protein — the "don't eat me" signal that cancer cells use to shield themselves from the immune system. Founded in 2015 by stem-cell pioneer Dr. Irv Weissman and colleagues, its lead drug, magrolimab, is a monoclonal antibody that blocks that signal so immune cells can attack tumors. The company's name is a playful nod to CD47, the very protein at the heart of its work.